Bionomics Limited
https://www.bionomics.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bionomics Limited
VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
New Company, Big Goal: Serial Entrepreneur Jonathan Lim Launches Erasca To 'Erase Cancer'
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
Pipeline Watch: Phase III Progress With Bempedoic Acid, Lefamulin, And Ibrutinib Combo
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Eclipse Therapeutics, Inc., Iliad Chemicals Pty Limited
- Bionomics, Inc.
- Prestwick Chemical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice